{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:24:27Z","timestamp":1790515467317,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1038\/nrrheum.2014.121","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T06:24:35Z","timestamp":1407219875000},"page":"691-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Rheumatoid arthritis and metabolic syndrome"],"prefix":"10.1038","volume":"10","author":[{"given":"Gy\u00f6rgy","family":"Kerekes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Seres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Paragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Kardos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsa","family":"Bar\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Tam\u00e1si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1l","family":"Solt\u00e9sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"key":"BFnrrheum2014121_CR1","first-page":"435","volume":"32","author":"PH Dessein","year":"2005","unstructured":"Dessein, P. H.  et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol. 32, 435\u2013442 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014121_CR2","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1161\/CIRCULATIONAHA.104.507996","volume":"112","author":"Y Shoenfeld","year":"2005","unstructured":"Shoenfeld, Y.  et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112, 3337\u20133347 (2005).","journal-title":"Circulation"},{"key":"BFnrrheum2014121_CR3","first-page":"398","volume":"35","author":"G Kerekes","year":"2008","unstructured":"Kerekes, G.  et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35, 398\u2013406 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014121_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.autrev.2009.02.015","volume":"8","author":"MT Nurmohamed","year":"2009","unstructured":"Nurmohamed, M. T. Cardiovascular risk in rheumatoid arthritis. Autoimmun. Rev. 8, 663\u2013667 (2009).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum2014121_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/ard.2009.113696","volume":"69","author":"MJ Peters","year":"2010","unstructured":"Peters, M. J.  et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325\u2013331 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014121_CR6","doi-asserted-by":"publisher","first-page":"710928","DOI":"10.1155\/2013\/710928","volume":"2013","author":"I Ferraz-Amaro","year":"2013","unstructured":"Ferraz-Amaro, I., Gonz\u00e1lez-Juanatey, C., L\u00f3pez-Mejias, R., Riancho-Zarrabeitia, L. & Gonz\u00e1lez-Gay, M. A. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm. 2013, 710928 (2013).","journal-title":"Mediators Inflamm."},{"key":"BFnrrheum2014121_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova, E.  et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann. Rheum. Dis. 70, 482\u2013487 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014121_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","volume":"9","author":"J Robertson","year":"2013","unstructured":"Robertson, J., Peters, M. J., McInnes, I. B. & Sattar, N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat. Rev. Rheumatol. 9, 513\u2013523 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum2014121_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrrheum.2011.107","volume":"7","author":"R G\u00f3mez","year":"2011","unstructured":"G\u00f3mez, R.  et al. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat. Rev. Rheumatol. 7, 528\u2013536 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum2014121_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrrheum.2009.219","volume":"5","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz, Z., Kerekes, G. & Solt\u00e9sz, P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat. Rev. Rheumatol. 5, 677\u2013684 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum2014121_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel, R. H., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 365, 1415\u20131428 (2005).","journal-title":"Lancet"},{"key":"BFnrrheum2014121_CR12","doi-asserted-by":"publisher","first-page":"e78151","DOI":"10.1371\/journal.pone.0078151","volume":"8","author":"J Zhang","year":"2013","unstructured":"Zhang, J.  et al. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS ONE 8, e78151 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2014121_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3109\/03009742.2011.626443","volume":"41","author":"VR da Cunha","year":"2012","unstructured":"da Cunha, V. R.  et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand. J. Rheumatol. 41, 186\u2013191 (2012).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum2014121_CR14","first-page":"2425","volume":"33","author":"PH Dessein","year":"2006","unstructured":"Dessein, P. H., Tobias, M. & Veller, M. G. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J. Rheumatol. 33, 2425\u20132432 (2006).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014121_CR15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/acr.21627","volume":"64","author":"F Wolfe","year":"2012","unstructured":"Wolfe, F. & Michaud, K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64, 1471\u20131479 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2014121_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrrheum.2010.105","volume":"6","author":"GD Summers","year":"2010","unstructured":"Summers, G. D., Metsios, G. S., Stavropoulos-Kalinoglou, A. & Kitas, G. D. Rheumatoid cachexia and cardiovascular disease. Nat. Rev. Rheumatol. 6, 445\u2013451 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum2014121_CR17","doi-asserted-by":"publisher","first-page":"R96","DOI":"10.1186\/ar4276","volume":"15","author":"PH Dessein","year":"2013","unstructured":"Dessein, P. H., Woodiwiss, A. J., Norton, G. R. & Solomon, A. Rheumatoid arthritis is associated with reduced adiposity but not with unfavorable major cardiovascular risk factor profiles and enhanced carotid atherosclerosis in black Africans from a developing population: a cross-sectional study. Arthritis Res. Ther. 15, R96 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2014121_CR18","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1002\/art.27629","volume":"62","author":"JT Giles","year":"2010","unstructured":"Giles, J. T.  et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 62, 3173\u20133182 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014121_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1053\/berh.2002.0257","volume":"16","author":"DP Symmons","year":"2002","unstructured":"Symmons, D. P. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract. Res. Clin. Rheumatol. 16, 707\u2013722 (2002).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2014121_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/acr.21749","volume":"65","author":"A Wesley","year":"2013","unstructured":"Wesley, A.  et al. Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: results from a population-based case\u2013control study. Arthritis Care Res. (Hoboken) 65, 107\u2013112 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2014121_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/ard.2007.078832","volume":"67","author":"AH van der Helm-van Mil","year":"2008","unstructured":"van der Helm-van Mil, A. H., van der Kooij, S. M., Allaart, C. F., Toes, R. E. & Huizinga, T. W. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann. Rheum. Dis. 67, 769\u2013774 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014121_CR22","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/art.22053","volume":"54","author":"PH Dessein","year":"2006","unstructured":"Dessein, P. H. & Joffe, B. I. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 54, 2765\u20132775 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014121_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/ard.2008.101964","volume":"68","author":"E Choy","year":"2009","unstructured":"Choy, E. & Sattar, N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 68, 460\u2013469 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014121_CR24","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/ar1952","volume":"8","author":"AN Georgiadis","year":"2006","unstructured":"Georgiadis, A. N.  et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment\u2014a prospective, controlled study. Arthritis Res. Ther. 8, R82 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2014121_CR25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/ard.2009.122374","volume":"69","author":"E Myasoedova","year":"2010","unstructured":"Myasoedova, E.  et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann. Rheum. Dis. 69, 1310\u20131314 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014121_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2009.07.015","volume":"207","author":"M Rizzo","year":"2009","unstructured":"Rizzo, M.  et al. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-na\u00efve patients with early rheumatoid arthritis. Atherosclerosis 207, 502\u2013506 (2009).","journal-title":"Atherosclerosis"},{"key":"BFnrrheum2014121_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00296-003-0358-4","volume":"24","author":"SH Kim","year":"2004","unstructured":"Kim, S. H.  et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol. Int. 24, 230\u2013233 (2004).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum2014121_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/1529-0131(199904)42:3<443::AID-ANR8>3.0.CO;2-Q","volume":"42","author":"Y Asanuma","year":"1999","unstructured":"Asanuma, Y., Kawai, S., Aoshima, H., Kaburaki, J. & Mizushima, Y. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum. 42, 443\u2013447 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014121_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/03009742.2012.745013","volume":"42","author":"TD Filippatos","year":"2013","unstructured":"Filippatos, T. D.  et al. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scand. J. Rheumatol. 42, 169\u2013175 (2013).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum2014121_CR30","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1002\/art.24802","volume":"60","author":"C Charles-Schoeman","year":"2009","unstructured":"Charles-Schoeman, C.  et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 60, 2870\u20132879 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014121_CR31","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/S0024-3205(03)00195-4","volume":"72","author":"N Tanimoto","year":"2003","unstructured":"Tanimoto, N.  et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72, 2877\u20132885 (2003).","journal-title":"Life Sci."},{"key":"BFnrrheum2014121_CR32","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1001\/jama.290.13.1709-c","volume":"290","author":"A Sch\u00e4ffler","year":"2003","unstructured":"Sch\u00e4ffler, A.  et al. Adipocytokines in synovial fluid. JAMA 290, 1709\u20131710 (2003).","journal-title":"JAMA"},{"key":"BFnrrheum2014121_CR33","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1136\/annrheumdis-2013-203587","volume":"72","author":"PH Dessein","year":"2013","unstructured":"Dessein, P. H., Norton, G. R., Woodiwiss, A. J. & Solomon, A. Independent relationship between circulating resistin concentrations and endothelial activation in rheumatoid arthritis. Ann. Rheum. Dis. 72, 1586\u20131588 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014121_CR34","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1253\/circj.68.975","volume":"68","author":"M Ryo","year":"2004","unstructured":"Ryo, M.  et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 68, 975\u2013981 (2004).","journal-title":"Circ. J."},{"key":"BFnrrheum2014121_CR35","doi-asserted-by":"publisher","first-page":"R161","DOI":"10.1186\/ar2844","volume":"11","author":"HM Choi","year":"2009","unstructured":"Choi, H. M.  et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res. Ther. 11, R161 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2014121_CR36","first-page":"461849","volume":"2013","author":"PH Dessein","year":"2013","unstructured":"Dessein, P. H., Norton, G. R., Badenhorst, M., Woodiwiss, A. J. & Solomon, A. Rheumatoid arthritis impacts on the independent relationships between circulating adiponectin concentrations and cardiovascular metabolic risk. Mediators Inflamm. 2013, 461849 (2013).","journal-title":"Mediators Inflamm."},{"key":"BFnrrheum2014121_CR37","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nri1937","volume":"6","author":"H Tilg","year":"2006","unstructured":"Tilg, H. & Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772\u2013783 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum2014121_CR38","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1136\/ard.2005.046540","volume":"65","author":"M Otero","year":"2006","unstructured":"Otero, M.  et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 1198\u20131201 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014121_CR39","first-page":"222","volume":"27","author":"MA Gonz\u00e1lez-Gay","year":"2009","unstructured":"Gonz\u00e1lez-Gay, M. A.  et al. Anti-TNF-\u03b1 therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin. Exp. Rheumatol. 27, 222\u2013228 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2014121_CR40","first-page":"56","volume":"28","author":"MA Gonz\u00e1lez-Gay","year":"2010","unstructured":"Gonz\u00e1lez-Gay, M. A.  et al. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-\u03b1 therapy. Clin. Exp. Rheumatol. 28, 56\u201362 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2014121_CR41","doi-asserted-by":"publisher","first-page":"R158","DOI":"10.1186\/ar3475","volume":"13","author":"K Kaneko","year":"2011","unstructured":"Kaneko, K.  et al. Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis. Arthritis Res. Ther. 13, R158 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2014121_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jbspin.2013.07.013","volume":"81","author":"YJ Ha","year":"2014","unstructured":"Ha, Y. J.  et al. Plasma chemerin levels in rheumatoid arthritis are correlated with disease activity rather than obesity. Joint Bone Spine 81, 189\u2013190 (2014).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum2014121_CR43","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/art.24789","volume":"61","author":"JT Giles","year":"2009","unstructured":"Giles, J. T., Allison, M., Bingham, C. O. 3rd, Scott, W. M. Jr & Bathon, J. M. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum. 61, 1248\u20131256 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014121_CR44","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/rheumatology\/kem291","volume":"46","author":"GS Metsios","year":"2007","unstructured":"Metsios, G. S.  et al. Blockade of tumour necrosis factor-\u03b1 in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 46, 1824\u20131827 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014121_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jbspin.2007.04.014","volume":"75","author":"M Soubrier","year":"2008","unstructured":"Soubrier, M.  et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 75, 22\u201324 (2008).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum2014121_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","volume":"41","author":"AM van Sijl","year":"2011","unstructured":"van Sijl, A. M.  et al. The effect of TNF-\u03b1 blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin. Arthritis Rheum. 41, 393\u2013400 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum2014121_CR47","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes, I. B.  et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann. Rheum. Dis. 73, 124\u2013131 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014121_CR48","first-page":"311","volume":"26","author":"MA Gonz\u00e1lez-Gay","year":"2008","unstructured":"Gonz\u00e1lez-Gay, M. A.  et al. Anti-TNF-\u03b1 therapy modulates resistin in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 311\u2013316 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2014121_CR49","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar597","volume":"4","author":"PH Dessein","year":"2002","unstructured":"Dessein, P. H., Joffe, B. I. & Stanwix, A. E. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res. 4, R12 (2002).","journal-title":"Arthritis Res."},{"key":"BFnrrheum2014121_CR50","first-page":"83","volume":"24","author":"MA Gonz\u00e1lez-Gay","year":"2006","unstructured":"Gonz\u00e1lez-Gay, M. A.  et al. Anti-tumor necrosis factor-\u03b1 blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24, 83\u201386 (2006).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2014121_CR51","first-page":"596","volume":"26","author":"MA Gonz\u00e1lez-Gay","year":"2008","unstructured":"Gonz\u00e1lez-Gay, M. A.  et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 596\u2013603 (2008).","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.121","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:34:06Z","timestamp":1684456446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2014.121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["BFnrrheum2014121"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2014.121","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,5]]},"assertion":[{"value":"5 August 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}